Market Cap 179.18M
Revenue (ttm) 680,000.00
Net Income (ttm) -45.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6,680.88%
Debt to Equity Ratio 0.00
Volume 1,764,000
Avg Vol 926,214
Day's Range N/A - N/A
Shares Out 67.36M
Stochastic %K 86%
Beta 1.40
Analysts Strong Sell
Price Target $10.00

Company Profile

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 952 7570
Address:
11055 Flintkote Avenue, San Diego, United States
Slowroast1
Slowroast1 Jan. 8 at 4:04 PM
$CRDF 3rd attempt at 3.30 with significant push back. We will see but if it doesnt break 3.30 soon, will drift lower with another attempt at it in a week or 2. My opinion of course
0 · Reply
Cutlass
Cutlass Jan. 8 at 3:41 PM
$CRDF Low volume stop hunt, we all knew they'd do that 😃
0 · Reply
CoveredBridge
CoveredBridge Jan. 8 at 3:18 PM
$CRDF It could simply be profit taking.
0 · Reply
Blakeruss1
Blakeruss1 Jan. 8 at 3:01 PM
$CRDF if holds 3.10 by end of day very bullish
0 · Reply
BubbaLubsGreen
BubbaLubsGreen Jan. 8 at 2:48 PM
Almost 200,000 shares of $CRDF have been traded today, in fewer than twenty minutes. 🧐
1 · Reply
Hurricane76
Hurricane76 Jan. 8 at 2:48 PM
$CRDF Rising tide lifts all boats... and this boat os already rising!
0 · Reply
cb28
cb28 Jan. 8 at 2:33 PM
$CRDF anyone have the details from asco yet?
0 · Reply
BubbaLubsGreen
BubbaLubsGreen Jan. 8 at 2:22 PM
$CRDF moved up yesterday partly because of a good day for XBI. XBI was mostly likely lifted by the wider market. Shorts have to be sweating through their sweater vests today. The stock market is pulling in stupid money now, which could easily raise CRDF’s share price. Not a lot of real shares available to buy, so when the squeeze comes, it will be mahem and carnage for the poor souls trying to exit what they thought would be winning bets.
0 · Reply
Cutlass
Cutlass Jan. 8 at 1:49 PM
$CRDF Oleo is Wishy-Washy 👇 🤠
1 · Reply
frogman2000
frogman2000 Jan. 8 at 1:25 PM
$CRDF as expected the panic is setting in for shorts and off exchange players. Total volume yesterday was around 1.7 M, off exchange volume was 864,000 and of that short volume was 550,000 making it 62% of total off exchange volume. Tons of manufactured liquidity for accumulation and some desperation for those playing the short game. Runway for this is drying up due to the low float. Intraday swaps like this will start to slow down.
1 · Reply
Latest News on CRDF
Cardiff Oncology: Preparing For A Defining 2026

Oct 25, 2025, 7:50 AM EDT - 2 months ago

Cardiff Oncology: Preparing For A Defining 2026


Cardiff Oncology: Data Update Resolves Some Signals

Jul 30, 2025, 11:32 AM EDT - 5 months ago

Cardiff Oncology: Data Update Resolves Some Signals


Cardiff Oncology Names Roger Sidhu as Medical Chief

Jun 17, 2025, 4:39 PM EDT - 7 months ago

Cardiff Oncology Names Roger Sidhu as Medical Chief


Cardiff Oncology: Buying The First-Line Onvansertib Strategy

May 14, 2025, 9:05 AM EDT - 8 months ago

Cardiff Oncology: Buying The First-Line Onvansertib Strategy


Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 9:10 PM EST - 11 months ago

Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript


Cardiff Oncology to Present at Upcoming Investor Conferences

Feb 24, 2025, 4:05 PM EST - 11 months ago

Cardiff Oncology to Present at Upcoming Investor Conferences


Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 11:18 AM EDT - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript


Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 8:06 PM EST - 2 years ago

Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call Transcript


Slowroast1
Slowroast1 Jan. 8 at 4:04 PM
$CRDF 3rd attempt at 3.30 with significant push back. We will see but if it doesnt break 3.30 soon, will drift lower with another attempt at it in a week or 2. My opinion of course
0 · Reply
Cutlass
Cutlass Jan. 8 at 3:41 PM
$CRDF Low volume stop hunt, we all knew they'd do that 😃
0 · Reply
CoveredBridge
CoveredBridge Jan. 8 at 3:18 PM
$CRDF It could simply be profit taking.
0 · Reply
Blakeruss1
Blakeruss1 Jan. 8 at 3:01 PM
$CRDF if holds 3.10 by end of day very bullish
0 · Reply
BubbaLubsGreen
BubbaLubsGreen Jan. 8 at 2:48 PM
Almost 200,000 shares of $CRDF have been traded today, in fewer than twenty minutes. 🧐
1 · Reply
Hurricane76
Hurricane76 Jan. 8 at 2:48 PM
$CRDF Rising tide lifts all boats... and this boat os already rising!
0 · Reply
cb28
cb28 Jan. 8 at 2:33 PM
$CRDF anyone have the details from asco yet?
0 · Reply
BubbaLubsGreen
BubbaLubsGreen Jan. 8 at 2:22 PM
$CRDF moved up yesterday partly because of a good day for XBI. XBI was mostly likely lifted by the wider market. Shorts have to be sweating through their sweater vests today. The stock market is pulling in stupid money now, which could easily raise CRDF’s share price. Not a lot of real shares available to buy, so when the squeeze comes, it will be mahem and carnage for the poor souls trying to exit what they thought would be winning bets.
0 · Reply
Cutlass
Cutlass Jan. 8 at 1:49 PM
$CRDF Oleo is Wishy-Washy 👇 🤠
1 · Reply
frogman2000
frogman2000 Jan. 8 at 1:25 PM
$CRDF as expected the panic is setting in for shorts and off exchange players. Total volume yesterday was around 1.7 M, off exchange volume was 864,000 and of that short volume was 550,000 making it 62% of total off exchange volume. Tons of manufactured liquidity for accumulation and some desperation for those playing the short game. Runway for this is drying up due to the low float. Intraday swaps like this will start to slow down.
1 · Reply
oligo
oligo Jan. 8 at 12:39 PM
$CRDF the previous data release wasn’t six month data. the data was supposed ”to come sooner” once 60 patients had two scans. there were ”problems” with the data collection review board that delayed the data release. it had nothing to do with a six month end point nor does it relate to a 12 month end point this quarter. they have not been forthcoming and are on their third rd director in less than two years. Seeing the world as you want to is fine for your own decisions but don’t misguide others. they are delaying and not being forthcoming. it bas been a PATTERN. there isn’t 12 month data coming. Roughly 30 patients have been dosed 12 months ago. full enrollment didn’t occur until april. you are not accurate. the separation is expected at about nine months not 18. So wrong again.
0 · Reply
PMD777
PMD777 Jan. 8 at 12:34 PM
$CRDF oligo incessantly posting and the ask getting dropped…SEC should look into this type garbage lol…jk they wouldn’t care
2 · Reply
oligo
oligo Jan. 8 at 12:17 PM
$CRDF @Goodstockday the previous data release wasn’t six month data. the data was supposed ”to come sooner” once 60 patients had two scans. there were ”problems” with the data collection review board that delayed the data release. it had nothing to do with a six month end point nor does it relate to a 12 month end point this quarter. they have not been forthcoming and are on their third rd director in less than two years. Seeing the world as you want to is fine for your own decisions but don’t misguide others. they are delaying and not being forthcoming. it bas been a PATTERN. there isn’t 12 month data coming. Roughly 30 patients have been dosed 12 months ago. full enrollment didn’t occur until april. you are not accurate. the separation is expected at about nine months not 18. So wrong again.
0 · Reply
PSDL75
PSDL75 Jan. 8 at 11:40 AM
$CRDF do we get another swipe at that resistance?
0 · Reply
Core366
Core366 Jan. 8 at 11:29 AM
$CRDF Because this person is always been butt hurt because they dont know how to enter and exit, and butt hurt because they wont take accountability with their own actions. Always crying like a child , or is short. Just report and.block that ignorant moron
2 · Reply
Goodstockday
Goodstockday Jan. 8 at 10:44 AM
$CRDF @oligo what a crazy post. They released 6mo post treatment data. Six months later, they will release 12 mo post treatment results. Standard treatment works for about 10 to 12 months. So, it will probably take until the 18 month mark to see really pronounced separation from SOC. Yet, the early depth of response numbers indicate we are very likely to see great things as the data matures. Nothing is being hidden!
3 · Reply
puck70
puck70 Jan. 8 at 10:42 AM
$CRDF 👇 short in panic modus 👇
0 · Reply
oligo
oligo Jan. 8 at 8:27 AM
$CRDF why not publish data for this long? because management has been hiding, clipping coupons and biding time (i.e. spending shareholders funds, collecting paychecks for pretending and hiding). if not, then why wait 6 months to show data on all its patients when it was willing yo show three month data on thirty patients? games to enrich themselves while not allowing shareholders to see their own data. they are enriching themselves. facts and history speaks for itself. just be careful and don’t ignore the facts.
1 · Reply
oligo
oligo Jan. 8 at 6:38 AM
$CRDF if this stock was a winner and truth be told is that I don’t think it will be anymore, then the large owners would press this stock at this point (and management would press information and this stock at this point because the chart is no longer their enemy and because the information is seasoned if there was anything worth showing), but that won’t be the case in my opinion and small investors should be careful not hopeful and plan for that. jpm’s hc conference is next week and if management wanted pm’s talking about their stock to other pm’s to help make their case and improve valuation and be put back on the radar and help future stock price levels, valuation and perception (which is important in this game) they would. the biotech and hc pm’s know this name as a long shot and a likely loser. look at the chart and it tells the story. management is clipping coupons. management is hiding, playing a shell game and collecting a salary. i’ve never been short the stock.
0 · Reply
oligo
oligo Jan. 8 at 6:32 AM
$CRDF if this stock was a winner and truth be told is that I don’t think it will be anymore than the large owners than the owners would press this stock at this point (and management would press information and this stock ag this point because the chart is no longer their enemy and because the information is seasoned if there was anything worth showing), but that won’t be the case in my opinion and small investors should be careful not hopeful and plan for that. jpm’s hc conference is next week and if management wanted pm’s talking about their stock to other pm’s to help make their case and improve valuation and be put back on the radar and help future stock price levels, valuation and perception (which is important in this game) they would. the biotech and hc pm’s know this name as a long shot and a likely loser. look at the chart and it tells the story. management is clipping coupons. management is hiding, playing a shell game and collecting a salary. i’ve never been short the stock.
0 · Reply
JuggernautRaider
JuggernautRaider Jan. 8 at 2:41 AM
$CRDF has had quite the turnaround story after being left for dead. Good luck Cardiff longs 🚀
1 · Reply
oligo
oligo Jan. 8 at 12:33 AM
$CRDF please be careful is my advice to people over their skis or people without money to lose. this is a risky play. odds are lower than vegas for crdf (lots). it has 90 percent plus chance if losing for a 0-7x return (not good). it’s been a shell game to-date at best. some say multi-disease state… i call foul on that characterization. they have failed several indications. failed studies are hidden. good safety profile is not the goal and if you look at the july data, safety isn’t assured here (neutropenia is an issue even if the more challenging patients got the drug). The company has been hiding studies (like most busts do) and believing their own postulations because they draw a salary rhat is large enough to be less than true. market makers have been so right it likely hasn’t been legal. just be careful. only small bets. the big boys and girls have small bets too just bigger balance sheets, but don’t be confused only small bets here other than ashton and santofi and both bailed.
1 · Reply